Sonelokimab shows promise for psoriatic arthritis

Sonelokimab, a single-domain antibody product, has achieved positive results from a Phase 2 trial of patients with active psoriatic arthritis. The ARGO trial, which enrolled 207 patients, met its primary endpoint with a statistically significant greater proportion of patients treated with the antibody achieving an American College of Rheumatology 50 response compared with those on a placebo at week 12. Secondary endpoints such as minimal disease activity also showed promising levels of response at week 12, according to the developer MoonLake Immunotherapeutics AG of Switzerland.